Stocklytics Platform
Asset logo for symbol NEO
NeoGenomics
NEO53
$13.78arrow_drop_down1.00%-$0.13
Asset logo for symbol NEO
NEO53

$13.78

arrow_drop_down1.00%

Income Statement (NEO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$20.39M-$28.16M-$9.70M-$19.94M-$23.74M
EBITDA-$2.29M-$9.90M$8.65M-$1.81M-$5.48M
gross Profit$69.04M$62.01M$67.58M$62.31M$59.89M
NET Income-$18.64M-$27.06M-$14.32M-$18.51M-$24.33M
total Revenue$164.50M$156.24M$155.55M$151.95M$146.91M

Balance Sheet (NEO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt$251.43M$276.26M$269.19M$299.46M$320.51M
stockholders Equity$915.88M$923.41M$941.53M$947.42M$956.19M
total Assets$1.64B$1.64B$1.68B$1.67B$1.69B
total Debt$606.51M$608.18M$611.67M$605.69M$609.58M
total Liabilities$727.39M$716.92M$739.69M$730.81M$738.91M

Cash Flow (NEO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$1.96M$816.00K$1.27M$1.84M$64.00K
free Cash Flow$814.00K-$31.50M$10.72M-$9.77M-$9.04M
investing Cash Flow----$14.94M
operating Cash Flow$13.89M-$25.91M$17.78M-$5.49M-$1.54M

NeoGenomics (NEO) Financials

NeoGenomics Inc (NEO) is a leading provider of cancer-focused genetic testing and information services. The company's income statement reflects its financial performance throughout a given period. It includes revenues, expenses, and net income from stockholders. Revenue represents the total amount of money earned by NeoGenomics through its operations. It is derived from the sale of genetic testing services and related products. The company's gross profit is the revenue minus the cost of sales. This metric indicates the profitability of NeoGenomics' core activities.
Earnings before interest and taxes (EBIT) is a measure of profitability that excludes the impact of interest and taxes. It gives insight into the operational performance of the company. NeoGenomics' EBITDA, or earnings before interest, taxes, depreciation, and amortization, further adjusts EBIT by excluding non-cash expenses like depreciation and amortization. This metric provides a clearer picture of the company's cash flow generation capacity.
NeoGenomics' balance sheet presents the company's financial position at a specific point in time. It encompasses assets, liabilities, and stockholders' equity. Total assets indicate the value of all resources owned by NeoGenomics. Cash equivalents represent highly liquid assets that can be easily converted to cash. Net debt is calculated as total debt minus cash and cash equivalents. It represents the company's overall debt position, taking its cash holdings into account. Stockholders' equity is the residual interest in NeoGenomics' assets after deducting liabilities. It reflects the shareholders' ownership value.
The total revenue figure represents the sum of all income generated by NeoGenomics during a period. It includes revenue from genetic testing services, additional service offerings, and other sources. Total debt refers to all contractual obligations that NeoGenomics owes to creditors. This can include long-term debt, short-term borrowings, and other liabilities. Total liabilities encompass all the company's debts and obligations, including both short-term and long-term liabilities.
Cash flow reflects the movement of cash into and out of NeoGenomics over a specified period. Operating cash flow represents the cash generated from the company's core operations. Investing cash flow shows the cash used for investment activities, such as acquiring new equipment or purchasing other businesses. Financing cash flow presents the cash flow resulting from NeoGenomics' financing activities, such as issuing new debt or repurchasing shares. Free cash flow measures the cash that remains after deducting capital expenditures from operating cash flow.
add NeoGenomics  to watchlist

Keep an eye on NeoGenomics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media